Efficacy and toxicity of the treatment of children and adolescents with Hodgkin Lymphoma by GPOH-HD-2002 protocol

D. A. Evstratov; Евстратов Д. А.; N. V. Myakova; Мякова Н. В.; A. V. Pshonkin; Пшонкин А. В.; Yu. G. Abugova; Абугова Ю. Г.; Yu. Yu. Dyakonova; Дьяконова Ю. Ю.; S. A. Radygina; Радыгина С. А.; N. М. Ershov; Ершов Н. М.; Yu. N. Likar; Ликарь Ю. Н.; L. A. Potapenko; Потапенко Л. А.; D. M. Konovalov; Коновалов Д. М.; G. V. Tereschenko; Терещенко Г. В.; V. V. Fominykh; Фоминых В. В.

doi:10.24287/1726-1708-2019-18-1-49-54

Efficacy and toxicity of the treatment of children and adolescents with Hodgkin Lymphoma by GPOH-HD-2002 protocol

Authors: Evstratov D.A.¹, Myakova N.V.¹, Pshonkin A.V.¹, Abugova Y.G.¹, Dyakonova Y.Y.¹, Radygina S.A.¹, Ershov N.М.¹, Likar Y.N.¹, Potapenko L.A.¹, Konovalov D.M.¹, Tereschenko G.V.¹, Fominykh V.V.¹
Affiliations:
1. Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation
Issue: Vol 18, No 1 (2019)
Pages: 49-54
Section: ORIGINAL ARTICLES
Submitted: 20.04.2019
Accepted: 20.04.2019
Published: 20.04.2019
URL: https://hemoncim.com/jour/article/view/225
DOI: https://doi.org/10.24287/1726-1708-2019-18-1-49-54
ID: 225

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

The reduction of long-term survival and fertility is still a problem in management of Hodgkin lymphoma in children and adolescents. These problems are partly solved by reduction of radiotherapy and changing procarbazine on etoposide and dacarbazine. We analyzed medical data of patients with HL < 18 years that were treated by modified OEPA-COPDAC protocol since 1.01.2012 to 01.12.2017. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. All patients despite gender didn't receive procarbazine. We analyzed data of 77 patients. Event-free survival (EFS) was 88% (95% CI 76.2-93.9%). EFS didn't differ between boys and girls 86.9% (95% CI 67.8-94.7%) and 88.7% (95% CI 67.3-96.1%) respectively (р = 0,9). EFS was significantly higher in patients without E-lesions compared with patients with E-lesions 90.8% (95% CI 77.8-96.2) and 72.7% (95% CI 28.4-89.6) respectively (p = 0.04). We analyzed toxicity of 40 cycles OEPA and 44 cycles COPDAC. Toxicity was acceptable. In our study we didn't detect significant difference in EFS in boys and girls. Procarbazine can be safely changed on etoposide in OPPA and dacarbazine in COPP in boys and girls with HL. E-lesions is a risk factor of inferior EFS.